Patents by Inventor LAURA ANN MCALLISTER

LAURA ANN MCALLISTER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS
    Publication number: 20180208608
    Abstract: The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: January 22, 2018
    Publication date: July 26, 2018
    Inventors: MICHAEL AARON BRODNEY, CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, CHRISTOPHER JOHN HELAL, STEVEN VICTOR O'NEIL, PATRICK ROBERT VERHOEST
  • 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
    Publication number: 20180065943
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • 5,7-Dihydro-Pyrrolo-Pyridine Derivatives
    Publication number: 20180002331
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
  • 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
    Patent number: 9845301
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: December 19, 2017
    Assignee: PFIZER INC.
    Inventors: Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert, Christopher John Helal, Douglas Scott Johnson, Justin Ian Montgomery, Steven Victor O'Neil, Bruce Nelsen Rogers, Patrick Robert Verhoest, Damien Webb
  • 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
    Publication number: 20170029390
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 2, 2017
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • KAT II inhibitors
    Patent number: 8933095
    Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: January 13, 2015
    Assignee: Pfizer Inc.
    Inventors: Amy Beth Dounay, Laura Ann McAllister, Vinod Dipak Parikh, Suobao Rong, Patrick Robert Verhoest
  • KAT ll INHIBITORS
    Publication number: 20140057938
    Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: Pfizer Inc.
    Inventors: AMY BETH DOUNAY, LAURA ANN MCALLISTER, VINOD DIPAK PARIKH, SUOBAO RONG, PATRICK ROBERT VERHOEST